ADAR1-Mediated RNA Editing and Its Role in Cancer

Jizhe Liu1,2, Fei Wang1,4, Yindan Zhang1,2,3, Jingfeng Liu5* and Bixing Zhao1,4*

1The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China, 2College of Life Science, Fujian Agriculture and Forestry University, Fuzhou, China, 3Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, China, 4Mengchao Med-X Center, Fuzhou University, Fuzhou, China, 5Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China

It is well known that the stability of RNA, the interaction between RNA and protein, and the correct translation of protein are significant forces that drive the transition from normal cell to malignant tumor. Adenosine deaminase acting on RNA 1 (ADAR1) is an RNA editing enzyme that catalyzes the deamination of adenosine to inosine (A-to-I), which is one dynamic modification that in a combinatorial manner can give rise to a very diverse transcriptome. ADAR1-mediated RNA editing is essential for survival in mammals and its dysregulation results in aberrant editing of its substrates that may affect the phenotypic changes in cancer. This overediting phenomenon occurs in many cancers, such as liver, lung, breast, and esophageal cancers, and promotes tumor progression in most cases. In addition to its editing role, ADAR1 can also play an editing-independent role, although current research on this mechanism is relatively shallowly explored in tumors. In this review, we summarize the nature of ADAR1, mechanisms of ADAR1 editing-dependent and editing-independent and implications for tumorigenesis and prognosis, and pay special attention to effects of ADAR1 on cancers by regulating non-coding RNA formation and function.

Keywords: ADAR1, RNA editing, cancer, non-coding RNA, adenosine to inosine

INTRODUCTION

A-to-I editing of RNA, a widespread co/post-transcriptional modification in mammals, is catalyzed by adenosine deaminases acting on RNA (ADARs) and has recently been recognized as an essential mechanism of cancer biology (Han et al., 2015; Baker and Slack, 2022). With the continuous increase of next-generation sequencing data, transcriptomics modifications, so-called RNA mutations, are becoming a significant force in promoting the transformation of normal cells into malignant tumors and providing tumor diversity to avoid immune attacks (Nishikura, 2010; Sagredo et al., 2018; Shevchenko and Morris, 2018). ADARs were first discovered in Xenopus laevis oocytes and embryos (Bass, 1987; Quin et al., 2021), confirming mediating editing of adenosine-to-inosine (A-to-I) in double-stranded (ds) RNA in mammals (Xu and Öhman, 2018). This edit acts as a functional A-to-G mutation by hydrolytic deamination at C6 of adenosine, changing it to inosine in the region of dsRNA (Figure 1A) (Nishikura, 2016).

By hydrolytically deaminating adenosine’s 6-position, ADARs catalyze the deamination of adenosine to inosine (Polson et al., 1991). An important target for A-to-I RNA editing is a dsRNA derived from inverted Alu repetitive elements (Alu dsRNA) (Athanasiadis et al., 2004; Bazak et al., 2014). Since cells interpret inosine (I) as guanosine (G), A-to-I editing can lead to non-synonymous codon changes in the transcript and alternative splicing (Walkley and Li, 2017;
In addition, ADARs can bind introns or 3′ untranslated regions (UTRs) to regulate the expression level of relative coding regions (Daniel et al., 2015; Sagredo et al., 2018). Still, it also affects targeting and disrupts the maturation of non-coding consequences, mainly microRNA, lncRNA, and circRNA (Velazquez-Torres et al., 2018; de Santiago et al., 2021; Shen et al., 2021). As a result of ADAR-mediated editing, which arises from mismatched A-to-I signatures after reverse transcription, more than 4 million edited positions have been identified (Bazak et al., 2014; Gallo et al., 2017).

Mammals have three ADAR genes, ADAR1 (also called ADAR, DRADA), ADAR2 (also called ADARB1), and ADAR3 (also called ADARB2), with specific structure, location, and function differences (Xu and Öhman, 2018; Shen et al., 2022). Currently, ADAR1 and ADAR2 have been shown to be expressed throughout most tissues and to be catalytically active, and the former mediates more editing events (Hogg et al., 2011). However, ADAR3 is specifically expressed in the brain and its function is only mentioned in a few articles (Melcher et al., 1996; Chen et al., 2000; Walkley and Li, 2017; Samuel, 2019). In glioblastoma, ADAR3 has been reported to be upregulated to competitively inhibit RNA editing at the Q/R site of GRIA2 by ADAR2 (Oakes et al., 2017; Wang et al., 2018). And these genes of the ADAR family have similar domain structures, mainly composed of a deaminase domain and two or three dsRNA binding domains (dsRBDs) (Erdmann et al., 2021; Quin et al., 2021). The deaminase domain of both ADAR1 and ADAR2 catalyzes the hydrolytic deamination of adenosine to inosine in dsRNA, while the catalytic activity of ADAR3 has not been reported so far (Chen et al., 2000; Nishikura, 2016; Oakes et al., 2017; Samuel, 2019). The dsRBD (~65 amino acids) binds directly to dsRNA through its own structural domain. In spite of the fact that both ADAR1 and ADAR2 have been shown to be associated with tumor progression, editing events regulated by ADAR1 are more strongly correlated with cancer development (Maas et al., 2001; Paz-Yaacov et al., 2015). There could be two main reasons for this result. One is that the enrichment of ADAR1 far exceeds that of ADAR2. ADAR1 expression was seen in nearly all tissues, while ADAR2 was most expressed in the brain, but more minor in other tissues (Paz-Yaacov et al., 2015). Significantly, ADAR1 is absolutely required, and ADAR1-null

FIGURE 1 | Catalytic function, domain organization, and shuttle mechanism of Adenosine Deaminase Acting on RNA 1 (ADAR1) (Created with BioRender.com). (A) RNA editing by ADARs. Alternative RNA editing by C6 deamination of adenosine (A) in the double-stranded RNA region to generate inosine (I), catalyzed by ADARs enzymes. (B) Schematic of the domain structure of two isoforms of ADAR1. ADAR1p150 and ADAR1p110 share identical sequence except for an additional N-terminal sequence for ADAR1p150, including an additional Zα domain (PDB: 2GDB) (Placido et al., 2007) and the NES which allows for both cytoplasmic and nuclear localization. Both contain a Zβ domain (PDB: 1XMK) (Athanasiadis et al., 2009) that mainly mediate Z-DNA/RNA binding, three dsRBDs domain (PDB: 2LJH, 2L2K, 2MDR) (Steff et al., 2010; Barraud et al., 2012; Barraud et al., 2014) that mediate dsRNA binding and homodimerization, and a deaminase domain (PDB: 1ZY7) (Macbeth et al., 2005) that is the catalytic center of ADAR1. (C) Cellular localization of ADAR1. XPO1 binds to NES located within the Zα structural domain and regulates nuclear export of ADAR1p150 in the presence of RAN-GTP. Nuclear import of ADAR1p110 is mediated by binding of TRN1 to dsRBD3. NLS located in the third dsRBD, a domain common to both ADAR1 isoforms, binds with TRN1 to assist in the targeting of ADAR1 in the nucleus.
mice die during embryonic life due to extensive apoptosis and
defective hematopoiesis (Hartner et al., 2004; Wang et al., 2004).
Furthermore, two is that human Adar1 maps to a single locus on
chromosome 1q21, whose amplification is the most common
cytogenetic abnormalities in multiple types of cancer and a poor
prognostic factor (Knuutila et al., 1998; Jiang et al., 2012; Teoh
et al., 2018).

ADARs editing is critical for survival in mammals, and its
dysregulation may contribute to cancer development (Ramírez-
Moya et al., 2021). The function of ADAR1-mediated RNA
editing in immunity, especially innate immunity, has been
summarized in many reviews (Lamers et al., 2019; Quin et al.,
2021; Song et al., 2022), so this article will not address this aspect
of the function. In addition to its editing role, ADAR1 can also
play an editing-independent role. Regardless of whether the
stability of ADARs regulatory RNAs is dependent on RNA
editing, RNA binding is essential for their action (Wang I. X
et al., 2013). Still, it will focus on the role of ADAR1 in cancer. For
example, ADAR1 is more abundant in lung, liver, esophageal and
chronic myelogenous leukemia, and with few exceptions, it
promotes cancer progression (Jiang et al., 2012; Qin et al.,
2014; Zhang et al., 2018; Sun et al., 2020). This review will
focus on the structure and regulatory mechanisms of the
ADAR1 enzymes and the relationship between aberrant editing
of specific substrates and tumorigenesis, especially
non-coding RNA.

NATURE OF ADENOSINE DEAMINASE
ACTING ON RNA 1

The human ADAR1 gene spans approximately 40 kb and
includes 17 exons, and the transcript level of ADAR1 is
increased by IFN or pathogen stimulation (George et al.,
2011). ADAR1 has two protein isoforms, full-length
ADAR1p150 (150 kDa) and shorter ADAR1p110 (110 kDa)
(Figure 1B) (Sun et al., 2021). Both contain a nuclear
localization signal (NLS), allowing nuclear localization
(Nishikura, 2016; Baker and Slack, 2022). In addition,
ADAR1p150 contains a nuclear export signal (NES),
accordingly shuttles between the nucleus and cytoplasm and is
predominantly cytoplasmic (Xu and Öhman, 2018; Sun et al.,
2021; Baker and Slack, 2022). Both isoforms contain a Zβ domain,
three dsRNA-binding domains and a deaminase catalytic domain
(George et al., 2011). 1) Zβ domain is a Z-DNA/RNA binding
domain which NLS locates in (Athanasiadis et al., 2005); 2)
dsRNA-binding domains (RI, RII, and RIII, ~65 amino acids),
which have an α-β-β-α configuration, make direct contact with
dsRNA (Thomas and Beal, 2017); 3) deaminase domain is the
catalytic center of ADAR1, in which the E912A point mutation in
ADAR1p150 (E617A for ADAR1p110) disrupts catalytic
deaminase activity (Wang I. X et al., 2013; Lamers et al., 2019;
Baker and Slack, 2022). Moreover, besides Zβ domain,
ADAR1p150 contains Zα domain, another Z-DNA/RNA
binding domain, which may have affected its binding
preferences (Nishikura, 2016; Sun et al., 2021). Notably,
shorter ADAR1p110 is constitutively expressed in ubiquitous
types of cells, whereas full-length ADAR1p150 is expressed only
when some activators stimulate cells, such as type I and type II
IFN (Rice et al., 2012; Li et al., 2016). Among the inverted
retrotransposon repeats of the long spacer nuclear element
(LINE) and short spacer nuclear element (SINE) families are a
number of endogenous long dsRNAs that are thought to be key-
acting substrate RNAs for ADAR1 (Liddicoat et al., 2015).
Moreover, the Alu motif mentioned above is a member of the
SINE family and is also one of the sites found to be subject to the
greatest extent and number of ADAR1 edits (Nishikura, 2010;
Liddicoat et al., 2015; Nishikura, 2016).

Although ADAR1p150 is primarily localized in the cytoplasm and
ADAR1p110 is predominantly localized in the nucleus, both
ADAR1p150 and ADAR1p110 shuttle between the nucleus and
cytoplasm (Figure 1C) (Streblov et al., 2002; Desterro et al.,
2003). The nuclear export factor exportin 1 (XPO1, also known as
CRM1) binds to the nuclear export signal (NES) located within the
Zα structural domain and regulates nuclear export of
ADAR1p150 in the presence of RAN-GTP (Poulsen et al.,
2001). The binding of transport protein 1 (TRN1) to
dsRBD3 mediates nuclear import of ADAR1p110, a process that is inhibited by dsRNA binding (Barraud et al., 2014).
The nuclear localization signal (NLS) located in the third dsRBD, a
domain common to both ADAR1 isoforms, binds with TRN1 to
assist in the targeting of ADAR1 in the nucleus (Fritz et al., 2009).

RNA EDITING-DEPENDENT OF
ADENOSINE DEAMINASE ACTING ON RNA 1 AND TUMORIGENESIS AND
PROGRESSION MECHANISMS

ADAR1 is frequently amplified in many diverse types of cancers
with elevated activity (Fritzell et al., 2018), including
hepatocellular carcinoma, non-small cell lung cancer, thyroid
cancer, pancreatic cancer, esophageal cancer, cervical cancer, and
multiple myeloma, and consistent with increased RNA editing
levels of its substrates (Chen et al., 2013; Han et al., 2015; Paz-
Yaacov et al., 2015; Chen Y et al., 2017; Hu et al., 2017; Sun et al.,
2020). Conversely, decreased ADAR1 expression was observed in
metastatic melanoma, invasive breast cancer, and kidney cancers
(Shoshan et al., 2015; Gumireddy et al., 2016). Most RNA editing
sites are located in noncoding regions or noncoding sequences and
therefore do not result in changes in protein sequence or
expression (Fritzell et al., 2018; Quin et al., 2021). However, a
small number of coding events still occur in the coding region,
thus affecting gene expression, or even if RNA editing occurs in
non-coding sequences, it may indirectly regulates gene expression
through mechanisms such as affecting the function of non-coding
RNAs. The focus of this section is on this particular editing events
by ADAR1 catalyzed, which contribute significantly to cancer
development and metastasis. And the content of this section is
divided into four main parts according to the differences in
calytic substrates, coding gene, intron, 3' UTR, and three
non-coding RNAs, including microRNA, lncRNA and
circRNA. In most cases, increased ADAR1 expression and/or
activity promotes cancer generation and progression; while in a few cancers, low expression and/or activity of ADAR1 mediating cancer phenotypes (Shoshan et al., 2015; Gumireddy et al., 2016).

We have compiled and summarized the prior literature that experimentally confirms the substrate, editing site, and effects of ADAR1 editing on cancer phenotypes (Table 1).

### Coding Genes

Early mechanistic studies on ADARs focused on causing protein recoding, which potentially modifies the amino acid sequence, thereby leading to decreased activity or acquisition of the encoded protein (Figure 2A). The coding sequence has a double-stranded structure on the exon, which is the region that may be subject to ADAR1-mediated A to I editing. The consensus editing site is AUU (Shigeyasu et al., 2018). In several of these cancers, ADAR1 over-edited AZIN1 RNA is an independent risk factor for lymph node and distant metastasis and may serve as a prognostic basis for overall survival and disease-free survival (Shigeyasu et al., 2018). In colorectal cancer, in addition to the above phenotypes, changes in cell stemness are also involved (Shigeyasu et al., 2018; Takeda et al., 2019).

### Table 1 | ADAR1 edits specific substrates involved in cancer progression.

| Gene          | Substrate type | Editing residues | Cancer                              | Hallmark                                      | References                                      |
|---------------|----------------|------------------|-------------------------------------|-----------------------------------------------|------------------------------------------------|
| ADAR1 promoting cancer |                |                  |                                     |                                               |                                                 |
| AZIN1         | Coding gene    | Y/C              | LIHC<sup>a</sup>                     | Growth, colony formation, invasion, migration | Chen et al. (2013)                              |
|               |                |                 | ESCC<sup>a</sup>                     |                                               | Qin et al. (2014)                              |
|               |                |                 | NSCLC<sup>a</sup>                    |                                               | Hu et al. (2017)                               |
|               |                |                 | CRC<sup>a</sup>                      | Growth, colony formation, invasion, stemness  | Shigeyasu et al. (2018), Takeda et al. (2019)  |
| BLCAP         | Coding gene    | Y/C, Q/R, K/R    | LIHC<sup>a</sup>                     | Proliferation, invasion, migration            | Hu et al. (2015)                               |
|               |                |                 | ESCC<sup>a</sup>                     | Invasion, migration                           | Chen W et al. (2017)                           |
|               |                |                 | MM<sup>a</sup>                       | Growth, metastasis, colony formation         | Jiang et al. (2012)                            |
|               |                |                 | MM<sup>a</sup>                       | Growth, colony formation, self-renewal        | Shimokawa et al. (2013), Lazzari et al. (2017) |
| NEIL1         | Coding gene    | K/R              | LIHC<sup>a</sup>                     | Inhibition                                    | Chen et al. (2013)                              |
| GLI1          | Coding gene    | R/G              | LIHC<sup>a</sup>                     | Invasion, migration                           | Hu et al. (2015)                               |
|               |                |                 | ESCC<sup>a</sup>                     | Invasion, migration                           | Chen W et al. (2017)                           |
|               |                |                 | MM<sup>a</sup>                       | Growth, metastasis, colony formation         | Jiang et al. (2012)                            |
|               |                |                 | MM<sup>a</sup>                       | Growth, colony formation, self-renewal        | Shimokawa et al. (2013), Lazzari et al. (2017) |
| ITGA2         | Coding gene    | NA<sup>a</sup>   | LIHC<sup>a</sup>                     | Invasion, migration                           | Chen et al. (2013)                              |
| CDK13         | Coding gene    | Q/R              | LIHC<sup>a</sup>                     | Proliferation, viability, invasion           | Hu et al. (2015)                               |
| FAK           | Intron         | Intron           | LIHC<sup>a</sup>                     | Growth, metastasis, colony formation         | Wang G et al. (2013)                           |
| ARHGAP26      | 3′ UTR         | 3′ UTR           | LIHC<sup>a</sup>                     | Growth, malignant transformation             | Wang G et al. (2013)                           |
| DHRF          | 3′ UTR         | 3′ UTR           | LIHC<sup>a</sup>                     | Growth, malignant transformation             | Wang G et al. (2013)                           |
| mIR-200b      | MRNA           | MRNA             | LIHC<sup>a</sup>                     | Proliferation, invasion, migration            | Nakano et al. (2017)                           |
| mRNA-149-3p   | MRNA           | MRNA             | LIHC<sup>a</sup>                     | Proliferation, invasion, migration            | Ramírez-Moya et al. (2020)                     |
| LINC00944     | LncRNA         | LncRNA           | LIHC<sup>a</sup>                     | Growth, proliferation, growth                | Yuje Ding et al. (2020)                        |
| PCA3          | LncRNA         | Duplex with PRUNE2 | LIHC<sup>a</sup>                     | Growth, proliferation, invasion              | de Santiago et al. (2021)                      |
| circNEIL3     | CircRNA        | CircRNA          | LIHC<sup>a</sup>                     | Proliferation, metastasis                     | Bussmakers et al. (1999)                       |
| circARSP91    | CircRNA        | CircRNA          | LIHC<sup>a</sup>                     | Growth, proliferation, metastasis            | Olive et al. (2009), Shen et al. (2021)        |
| hsa_circ_0004872 | CircRNA  | CircRNA          | GC<sup>a</sup>                       | Metastasis, colony formation                 | You et al. (2015), Shi et al. (2017)           |

**ADAR1 suppressing cancer**

| Gene          | Substrate type | Editing residues | Cancer                              | Hallmark                                      | References                                      |
|---------------|----------------|------------------|-------------------------------------|-----------------------------------------------|------------------------------------------------|
| GABRA3        | Coding gene    | I/M              | BRCA<sup>a</sup>                     | Migration/invasion                            | Gumireddy et al. (2016)                         |
| CCNI          | Coding gene    | R/G              | MEL<sup>a</sup>                      | Activates of TIL                              | Zhang et al. (2018)                            |
| DFFA          | 3′ UTR         | 3′ UTR           | BRCA<sup>a</sup>                     | Infection, invasion                           | Roberts et al. (2018)                          |
| mIR-455-5p    | MRNA           | MRNA             | MEL<sup>a</sup>                      | Growth, metastasis                            | Shoshoan et al. (2015)                         |
| mIR-378a-3p   | MRNA           | MRNA             | CCNI<sup>a</sup>                     | Invasion, migration                           | Velaquez-Torres et al. (2018)                   |
| mIR-222       | MRNA           | MRNA             | DFFA<sup>a</sup>                     | Growth and metastasis                         | Gaïore-Haskell et al. (2015)                    |

<sup>a</sup>NA, not available; LIHC, liver hepatocellular carcinoma; ESCC, esophageal squamous cell carcinoma; NSCLC, non-small-cell lung cancer; CRC, colorectal carcinoma; ESCC, esophageal squamous cell carcinoma and endocervical adenocarcinoma; MM, multiple myeloma; TC, thyroid cancer; LUAD, lung adenocarcinoma; BRCA, breast invasive carcinoma; PRAD, prostate adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma; GC, gastric cancer; MEL, melanoma.
FIGURE 2 | Possible regulatory mechanisms for RNA editing-dependent and editing-independent of ADAR1 involved in tumorigenesis and progression (Created with BioRender.com). (A) The dsRNA hairpin structures formed in the exonic region of the encoded gene are recognized by ADAR1. It undergoes A-to-I editing, and splicing machinery interprets inosine as guanosine, which leads to inactivation or activation of the final translation product. (B) ADAR1 binds to the intron of pre-mRNA, resulting in increased abundance of exon. (C) By editing intronic fold-back dsRNAs with A-to-I editing, splice sites could be created or deleted, leading to the inclusion or exclusion of Alu exons. (D) ADAR1 interacts with HuR proteins to coregulate common transcripts. (E) Editing of the 3′UTR can change the stability of the mRNA by creating or destroying the binding site of the miRNA. I: acquired the ability to bind miRNA; II: loss of the ability to bind miRNA. (F) ADAR1 competes with (Continued)
cancers and is a novel ADAR-mediated editing substrate in hepatocellular carcinoma and cervical cancer (Hu et al., 2015; Chen W et al., 2017). Over-editing of BLCAP was found in 40.1% HCCs compared to adjacent liver tissues. And RNA-edited BLCAP may stably promote cell proliferation by activating AKT/mTOR signal pathway (Hu et al., 2015). In cervical cancers, editing events by ADAR1 alter the genetically coded amino acid in BLCAP YXXQ motif, inducing BLCAP to lose the inhibition to signal transducer and activator of transcription 3 (STAT3) activation, which drives the carcinogenesis progression (Chen W et al., 2017). However, compared with the related normal tissues, BLCAP edited isoforms were reduced in astrocytoma, bladder cancer and colorectal cancer, indicating that the RNA editing level of BLCAP differs in different tumors (Meng et al., 2017).

However, in contrast to the above examples, in some cancers, such as breast cancer, melanoma, RNA editing of ADAR1 inhibits cancer development. In other words, low levels of ADAR1 editing in certain cancers lead to poor prognosis of patients (Gumireddy et al., 2016; Nishikura, 2016; Zhang et al., 2018; Baker and Slack, 2022). ADAR1-edited Gabra3 was only in non-invasive breast cancer and showed that edited Gabra3 reduced the abundance of wild-type Gabra3 on the cell surface and inhibited AKT activation, thereby suppressing breast cancer cell invasion and metastasis (Gumireddy et al., 2016). In melanoma, the ADAR1-edited cell cycle protein 1 (CCN1) R75G peptide activates tumor-infiltrating lymphocytes (TIL) and promotes TIL killing of cancer cells (Zhang et al., 2018).

To summarize, the above findings suggest that the expression of ADAR1 varies depending on the coding gene and cancer type. Whether ADAR1 overexpression or over-editing promotes or prevents cancer progression depends on the type of editing substrates, their level of expression, and how they participate respectively in regulating malignant changes in cancer cells.

Intron

The intron in certain coding regions has also been shown to recognize and bind to ADAR1 before being spliced and promote exon expression in an editing-dependent manner. A few articles have reported this approach, and the mechanisms have not been explored in detail (Figure 2B). ADAR1 post-transcriptionally increased the abundance of focal adhesion kinase (FAK) protein by binding and editing to a specific intronic site on chr8: 141,702,274 in FAK transcript, resulting in the increased stabilization of FAK mRNA, thereby promoting mesenchymal properties, migration, and invasion of lung adenocarcinoma (Amin et al., 2017).

RNA editing of Alu-rich intron regions may lead to Alu exonization, which controls mRNA levels and translation efficiency and potentially leads to disease (Figure 2C) (Lev-Maoz et al., 2007; Sakurai et al., 2010). However, this modality is only found in G protein-coupled receptor 107 (Athanasiadis et al., 2004), nuclear prelamin A (Lev-Maoz et al., 2007) and seryl-tRNA synthetase (Sakurai et al., 2010). However, there is no evidence that ADAR1 mediates cancer-associated gene exonization.

3′ Untranslated Region

There are two main ways ADAR1-catalyzed editing on the 3′ UTR influences gene expression regulation. A relatively common one is editing of Alu dsRNA on the 3′ UTR, which binds to and is regulated by microRNA when unedited. The other is dependent on editing to alter the stability of the mature mRNA, mainly achieved by the recruitment of HuR proteins with ADAR1 (Figure 2D) (Song et al., 2016). RNA editing events that occur in the 3′UTR of mRNAs may alter their interactions with miRNAs. Within the 3′ UTRs of mRNAs from nine different types of cancer, Pinto et al. identified over 63,000 editing sites that harbor Alu dsRNAs that serve as recruitment signals for ADAR (Pinto et al., 2018). Several studies have established that RNA editing that occurs in the 3′UTR can create or disrupt miRNA binding sites, thereby altering the mRNA stability of cancer-related genes (Figure 2E) (Li and Landweber, 2007; Borchert et al., 2009).

For instance, 3′ UTR of Rho GTPase activating protein 26 (ARHGAP26) transcript undergoes ADAR1-catalyzed extensive A-to-I RNA editing (Wang Q et al., 2013). Known as a cancer suppressor, ARHGAP26 activates Rho GTPases (Zhong et al., 2019). Undergone A-to-I editing, the 3′ UTR of ARHGAP26 failed to pair with miR-30b-3p and miR-573, thus translating without interference, thereby promoting breast cancer growth and malignant transformation (Wang Q et al., 2013). As a counterexample, ADAR1, which is much less expressed in breast cancer, targets the 3′ UTR of DNA fragmentation factor subunit alpha (DFFA) transcript, therefore promoting cancer cell invasion (Roberts et al., 2018). DFFA is an inhibitor of caspase-activated DNase (ICAD) that triggers DNA fragmentation during apoptosis (Fawzy et al., 2017). In non-invasive, hormone-responsive breast cancer cell lines, editing of DFFA mRNA by ADFA1 rendered the mRNA unrecognized by miR-140-3p, thereby increasing DFFA levels and inducing
apoptosis, whereas lack of editing in highly invasive, triple-negative breast cancer cell lines prevented DFFA from being regulated by miR-1403p (Roberts et al., 2018).

Altered RNA stability is an essential mechanism for ADAR1-mediated regulation of gene expression. ADAR1 recruits and interacts with human antigen R (HuR, gene name ELAVL1), a family of RNA-binding proteins selectively binds to single-stranded AU-rich RNA sequences (de Silanes et al., 2003; Meisner et al., 2004), to increase transcript stability (Figure 2D) (Wang I. X et al., 2013). It is estimated that 3’ UTR of up to 8% of all mRNAs contain AU-rich elements, including genes for cancer progression (Shaw and Kamen, 1986; Shaw et al., 2006). Among the 775 genes whose expression levels decreased after ADAR1 knockdown, the genes containing HuR binding sites showed significantly higher expression than the others (Wang I. X et al., 2013), such as MCM4 (Bagley et al., 2012), TMPO (Li et al., 2014; Ramírez-Moya et al., 2020). ADARs can also bind and edit some non-coding genes that contain inverted Alu repeats or LINE of non-coding genes, such as microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA) to suppress non-coding RNA maturation (Torsin et al., 2021).

**Non-Coding RNA**

Currently, dysregulated levels of non-coding RNAs (ncRNAs) appear to be reported for every type of cancer, and non-coding transcripts are expected to be the next class of diagnostic and therapeutic tools in oncology (Song et al., 2016; Shen et al., 2022). In addition to RNA editing mediated amino acid substitutions in specific genes contributing to cancer, elevated ADAR1 editing of non-coding RNAs, can also promote cancer progression (Qi et al., 2014; Ramírez-Moya et al., 2020). ADARs can also bind and edit some non-coding genes that contain inverted Alu repeats or LINE of non-coding genes, such as microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA) to suppress non-coding RNA maturation (Torsin et al., 2021).

**MicroRNA**

According to their binding sites along with RNA transcripts, ADAR1 protects mRNA from degradation, regulates miRNA processing, and alters splicing patterns (Xu and Ohman, 2018).

It has been shown that ADAR1 interacts with Dicer or DCGR8 to mediate processing of pre-miRNAs, ultimately leading to microRNA destabilization (Bahn et al., 2015). In this way, the editing of certain microRNA precursors results in lower levels of expression or altered function of mature miRNAs, thereby leading to alterations in certain cancer phenotypes (Figure 2G). In thyroid cancer cells, ADAR1-dependent editing miR-200b exhibits a lower activity against its target ZEB1-3’ UTR, which facilitates the epithelial–mesenchymal transition, thus resulting in proliferation, invasion, and migration of thyroid tumor cells (Ramírez-Moya et al., 2020). In melanoma cells, ADAR1p150 directly interacted with Dicer, an enzyme cleave precursor miRNA (usually 70 nt) to form mature miRNA (around 22 nt), which increased the cleavage rate of pre-miRNA and promoted the loading and maturing of miRNA (Chiosea et al., 2006), thereby promoting the biosynthesis and function of miRNA-149-3p (Yujie Ding et al., 2020). The expression of GSK3α, a direct target of miR-149-3p, is decreased, eventually resulting in proliferation of melanoma cells and inhibited cell apoptosis (Yujie Ding et al., 2020).

Likewise, modification of certain microRNAs by ADAR1 can exert a suppressive effect on cancer, and such miRNAs tend to be less expressed in cancerous tissues with a high metastatic capacity (Shoshan et al., 2015; Velazquez-Torres et al., 2018; Xu and Ohman, 2018). For example, with high levels of A-to-I editing in low metastatic melanoma but not in high metastatic melanoma, edited miR-455-5p lost the binding site of its downstream cancer suppressor protein CPEB1, which resulted in the suppression of melanoma growth and metastasis (Shoshan et al., 2015). Only in non-metastatic melanoma cells, edited miR-378a-3p predominantly binds to and represses the expression of the 3’-UTR of the PARVA oncogene, thereby inhibiting the progression of melanoma to a malignant phenotype (Velazquez-Torres et al., 2018).

**Long Non-Coding RNA**

Recently, LncRNAs have been shown to be central regulators of gene expression in a variety of genes (Guo et al., 2020). The LncRNAs involved in oncogenes and tumor suppressors are modified by A-to-I RNA editing machinery, with modifications that are drastically altered in cancer cells (Silvestris et al., 2020). ADAR1 can change RNA expression levels by interacting with other RNA-binding proteins, such as Dicer (Deng et al., 2019) and HuR (Stellos et al., 2016), the same mechanism as the 3’ UTR and the miRNA described previously. In addition, editing of dsRNA on LncRNA by ADAR1 changes its structure, which affects the binding of downstream target miRNAs (Figure 2H). Exceptional cases are reported in the literature where lncRNAs are recognized and edited by ADAR1 after complementary pairing with mRNA bases (Figure 2H) (Bussemakers et al., 1999).

The expression of ADAR1-regulated lncRNA LINC00944 is immune-related in breast cancer cells. LINCO0944 expression was positively correlated to tumor infiltrating T lymphocytes, the age at diagnosis, tumor size, and poor prognosis (de Santiago et al., 2021). In spite of the variations in LINCO0944 expression corresponding to up and down regulation of ADAR1, it is unknown the regulatory mechanism of ADAR1 for this lncRNA (de Santiago et al., 2021).

Prostate cancer antigen 3 (PCA3), a long non-coding RNA, is upregulated in human prostate cancer (Bussemakers et al., 1999). PCA3 regulates the level of PRUNE2 through a unique regulatory mechanism that involves the formation of PRUNE2/ADAR1-edited PCA3 double-stranded RNA. Editing by ADAR1 at multiple sites in the PCA3/PRUNE2 duplex results in a reduction of PRUNE2, and an increase in PCA3 expression, therefore increasing in cancer cell the ability of cancer cell, such as proliferation, adhesion and migration (Bussemakers et al., 1999).

**Circular RNA**

As mentioned above, ADAR1 interacts with by binding to the inverse complementary dsRNA, such as Alu repeat region; circRNAs can also interact with it in this way (Chen and Yang, 2015). ADAR1 creates or disrupts splice sites by acting on dsRNA editing, thereby inhibiting circRNA cyclization (Figure 2I) (Zhang and Carmichael, 2001; Fritz et al., 2009; Shevchenko and Morris, 2018).

CircNEIL3 and ADAR1 are upregulated in pancreatic ductal adenocarcinoma (PDAC) cells and tissues, and circNEIL3 as a
miRNA sponge leads to down-regulation of miR-432-5p, thereby suppressing the down-regulation effect caused by the 3'UTR interaction of this microRNA with ADAR1 (Xu et al., 2020; Shen et al., 2021). Subsequently, ADAR1 enhances GLI1 editing, which promotes the transcription of target genes, including cyclin D1, cyclin E and Snail, and the cyclin-dependent kinases CDK2, CDK4 and CDK6 afterward decreased (Olive et al., 2009; Wang et al., 2020; Shen et al., 2021). In summary, the circNEIL3/miR-432-5p/ADAR1/GLI1/cyclin D1/CDK axis regulates the proliferation and metastasis of PDAC via the downstream GLI1/cyclin D1 and EMT pathway (Olive et al., 2009; Shen et al., 2021).

In addition, ADAR1 has been described to repress circRNA production intensely, and its A-I editing process usually occurs near reverse complementary matches (RCMs) in circRNA flanking introns, A structure essential for circRNA cyclization (Shi et al., 2017; Ma et al., 2020). Through this editing, secondary structures between RCMs could be stronger or weaker respectively depending on whether correcting A:C was mismatched to I(G)-C pairs or I(G) U pairs (Shen et al., 2022).

Androgen receptor (AR), a transcriptional activator of ADAR1 promoter, could suppress circARSP91 expression by upregulating ADAR1 p110, eventually leading to HCC tumor growth both in vitro and in vivo (You et al., 2015; Shi et al., 2017). Circular RNA hsa_circ_0004872, dramatically downregulated in gastric cancer, molecular sponges miR-224 to upregulate the expression of the miR-224 downstream targets p21 and Smad4 by targeting the 3'-UTR (Ma et al., 2020). Smad4, as a transcription factor, could inhibit ADAR1 expression level by directly binding to the promoter region of ADAR1, thereby further upregulating hsa_circ_0004872 levels. In other words, Smad4/ADAR1/hsa_circ_0004872/miR-224/Smad4 axis regulated tumor size and local lymph node metastasis in gastric cancer (Hansen et al., 2013; Zhu et al., 2017; Ma et al., 2020).

ADAR1 can edit reverse complementary matches (RCM) of ADAR1-regulated circRNAs, altering the secondary structure formed between RCMs within the flanking introns and enhancing the binding of RNA-binding proteins (RBPs) to the site of action (Kristensen et al., 2019; Shen et al., 2022). And the different expression of ADAR1 leads to editing dysregulation of A-to-I RNA editome in multiple cancers, such as HCC, ESCC, CRC, and GC (Qin et al., 2014; Han et al., 2020; Song et al., 2021). These ADAR1-regulated circRNAs are not byproducts of reverse splicing but important molecules that influence cancer development and progression.

RNA EDITING-INDEPENDENT OF ADENOSINE DEAMINASE ACTING ON RNA 1 AND TUMORIGENESIS AND PROGRESSION MECHANISMS

The most direct role of ADAR1 relies on A-to-I editing, which can alter coding sequences, binding motifs, RNA structure, etc., to regulate substrate abundance. However, ADARs have also been shown to have an editing-independent role, as they can also function as RNA-binding proteins independent of catalytic activity (Nishikura, 2016).

In melanoma, ADAR1 controls the expression of integrin beta 3 (ITGB3), a cell surface protein associated with tumor invasion (Pinon and Wehrle-Haller, 2011; Orgaz and Sanz-Moreno, 2013), via miR-22 and PAX6 transcription factor at the post-transcriptional and transcriptional levels. The expression and functional output of both FOXD1, which controls miR-22 expression, and PAX6 are independent of RNA editing, therefore promoting growth and invasion of melanoma (Nemlich et al., 2018).

In cytoplasm, binding of the targeted 3' UTR allows phosphorylated ADAR1p110 to preclude binding of Staufen1 and subsequent decay of the anti-apoptotic gene, thereby promoting survival of stressed cells in an editorially independent manner (Figure 2F) (Sakurai et al., 2017). It has been reported in the literature that Staufen1 has positive or negative effects on disease progression: in some malignancies, upregulated Staufen1 may act as an oncogene and promote cancer progression (Boulay et al., 2014; Xu et al., 2015; Crawford Parks et al., 2017); while in other cancers, Staufen1 may act as a tumor suppressor and inhibit disease progression (Gong and Maquat, 2011; Boulay et al., 2014; Su et al., 2020). Nevertheless, reports on the mechanism of ADAR1 for Staufen1 have not yet appeared in cancer. Interaction of IncRNA with Staufen1 has also been reported in a variety of cancers (Sakurai et al., 2017); however again no mechanism of action of ADAR1 for Staufen1 in tumors has been reported. In HCC, ADAR1 was detected to interact directly with Dicer without editing, resulting in the processing of pre-miR-27a (Qi et al., 2017). Mature miR-27a binds to the 3'-UTR of methyltransferase 7A (METTL7A), a known tumor suppressor, decreasing its expression level (Qi et al., 2017). In addition, ADAR1 can regulate miRNA processing in an RNA-binding but editing-independent manner. ADAR1 can indirectly affect miRNA biogenesis by regulating Dicer expression at the translational level through the Let-7 gene (let-7) (Zipeto et al., 2016).

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

In conclusion, we show the structure and regulatory mechanisms of the ADAR1, and the significant role of ADAR1 in regulating many aspects of RNA function in cancers, including regulating the biogenesis of coding gene, intron, 3' UTR, and three prevalent non-coding RNA, such as miRNA, IncRNA, circRNA. However, many important questions remain in the field including: 1) What are the factors that influence altered ADAR1 expression in cancer, and how do they play a role? 2) There are many editing-independent mechanisms of action in cancer that exist only in theory and for which there is no clear experimental evidence. 3) Up-regulation of ADAR1 expression promotes cancer development and progression in most cases, and down-regulation of ADAR1 in some cases can also achieve cancer progression. How do cancer cells control the abundance of ADAR1 so precisely to enhance their progression? Future investigation of these issues may lead to further discoveries in A-to-I RNA editing.
AUTHOR CONTRIBUTIONS

BZ and JZL conceived the content and wrote the manuscript. FW and YZ contributed to the figures and the literature collection. BZ and JZL supervised the overall project and edited the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

Amin, E. M., Liu, Y., Deng, S., Tan, K. S., Chudgar, N., Mayo, M. W., et al. (2017). The RNA-Editing Enzyme ADAR Promotes Lung Adenocarcinoma Migration and Invasion by Stabilizing FAK. Sci. Signal. 10, eaah3941. doi:10.1126/scisignal.aah3941

Athanasiadis, A., Placido, D., Maas, S., Brown, B. A., Lowenhaupt, K., and Rich, A. (2005). The Crystal Structure of the Zf Domain of the RNA-Editing Enzyme ADAR1 Reveals Distinct Conserved Surfaces Among Z-Domains. J. Mol. Biol. 351, 496–507. doi:10.1016/j.jmb.2005.06.028

Bahn, J. H., Keane, T. M., Maklakova, V. I., Marshall, J. G., Lester, R. A., Cancel, M. M., et al. (2012). A Dominantly Acting Murine Allele of Mcm4 Causes Chromosomal Abnormalities and Promotes Tumorigenesis. PLoS Genet. 8, e1003034. doi:10.1371/journal.pgen.1003034

Bahn, J. H., Ahn, J., Lin, X., Zhang, Q., Lee, J.-H., Civelek, M., et al. (2015). Genomic Analysis of ADAR1 Binding and its Involvement in Multiple RNA Processing Pathways. Nat. Commun. 6, 6355. doi:10.1038/ncomms7355

Bahn, J. H., Lee, J.-H., Li, G., Greer, C., Peng, C., and Xiao, X. (2012). Accurate Overexpression of Dicer, a Component of the MicroRNA Machinery, in Prostate Adenocarcinoma. Am. J. Pathology 180, 1812–1820. doi:10.2353/ajpath.2012.060480

Chen, C.-X., Cho, D.-S. C., Wang, Q., Lai, F., Carter, K. C., and Nishikura, K. (2003). Role of the RNA-Binding Protein HuR in Colon Carcinogenesis. Nucleic Acids Res. 31, D111–D114. doi:10.1093/nar/gkj052

Chen, W., He, W., Cai, H., Hu, B., Zheng, C., Ke, X., et al. (2017). A-to-I RNA Editing of BLCAp Lost the Inhibition to STAT3 Activation in Cervical Cancer. Oncotarget 8, 39417–39429. doi:10.18632/oncotarget.17034

Chen, Y., Wang, H., Lin, W., and Shuai, P. (2017). ADAR1 Overexpression Is Associated with Cervical Cancer Progression and Angiogenesis. Diagn Pathol. 12, 12. doi:10.1186/s13000-017-0600-0

Cheng, L.-L., and Yang, L. (2015). Regulation of circRNA Biogenesis. RNA Biol. 12, 381–388. doi:10.1080/15476286.2015.102071

Chen, L., Li, Y., Lin, C. H., Chan, T. H. M., Chow, R. K. K., Song, Y., et al. (2013). Recoding RNA Editing of AZIN1 Predisposes to Hepatocellular Carcinoma. Nat. Med. 19, 209–216. doi:10.1038/nm.3043

Chen, W., He, W., Cai, H., Hu, B., Zheng, C., Ke, X., et al. (2017). A-to-I RNA Editing of BLCAp Lost the Inhibition to STAT3 Activation in Cervical Cancer. Oncotarget 8, 39417–39429. doi:10.18632/oncotarget.17034

Chen, Y., Wang, H., Lin, W., and Shuai, P. (2017). ADAR1 Overexpression Is Associated with Cervical Cancer Progression and Angiogenesis. Diagn Pathol. 12, 12. doi:10.1186/s13000-017-0600-0

Chiosea, S., Jelezcova, E., Chandran, U., Acquafondata, M., Macobe, T., Sobol, R. W., et al. (2006). Up-Regulation of Dicer, a Component of the MicroRNA Machinery, in Prostate Adenocarcinoma. Am. J. Pathology 164, 1812–1820. doi:10.1016/j.ajpath.2006.06.028

Crawford Parks, T. E., Marcellus, K. A., Langill, J., Ravel-Chapuis, A., Michaud, J., Crowen, K. N., et al. (2017). Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma via C-myc-dependent and -independent Events. Sci. Rep. 7, 42342. doi:10.1038/srep42342

Daniel, C., Lagergren, J., and Öhman, M. (2015). RNA Editing of Non-coding RNA and its Role in Gene Regulation. Biochimie 117, 22–27. doi:10.1016/j.bjio.2015.05.020

de Santiago, P. R., Blanco, A., Morales, F., Marcelino, K., Harismendy, O., Sjöberg, Herrera, M., et al. (2021). Immune-related IncRNA LINC00944 Responds to Variations in ADAR1 Levels and it Is Associated with Breast Cancer Prognosis. Life Sci. 268, 118956. doi:10.1016/j.lfs.2020.118956

de Silanes, J. L., Fan, J., Yang, X., Zonderman, A. B., Potapova, O., Pizer, E. S., et al. (2003). Role of the RNA-Binding Protein HuR in Colon Carcinogenesis. Oncogene 22, 7146–7154. doi:10.1080/09609862

Deng, S.-J., Chen, H.-Y., Zeng, Z., Deng, S., Zhu, S., Ye, Z., et al. (2019). Nutrient Stress-regulated Antisense IncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Cancer Res. 79, 1398–1412. doi:10.1158/0008-5472.CAN-18-0419

Destroero, J. M. P., Keegan, L. P., Lafarga, M., Berciano, M. T., O’Connell, M., and Carmin-Fonseca, M. (2003). Dynamic Association of RNA-Editing Enzymes with the Nucleolus. J. Cell Sci. 116, 1805–1818. doi:10.1242/jcs.00371

Dong, X., Chen, G., Cai, Z., Li, Z., Qiu, L., Xu, H., et al. (2018). CDK13 RNA Over-editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients. Cell Physiol. Biochem. 47, 2002–2012. doi:10.1159/000419656

Eisenberg, E., and Levanon, E. Y. (2018). A-to-I RNA Editing - Immune Protectome and Transcriptome Diversifier. Nat. Rev. Genet. 19, 473–490. doi:10.1038/s41576-018-0066-1

Erdmann, E. A., Madapratap, A., Mukherjee, P., Yang, B., and Hundle, H. A. (2021). To Protect and Modify Double-Stranded RNA - the Critical Roles of ADARs in Development, Immunity and Oncogenesis. Crit. Rev. Biochem. Mol. Biol. 56, 54–87. doi:10.1080/10409288.2020.1856768

Fawzy, M. S., Toraih, E. A., Ibrahiem, A., Abdeldayem, H., Mohamed, A. O., and Abdel-Daim, M. M. (2017). Evaluation of miRNA-196a2 and Apoptosis-Related Target Genes: ANXA1, DFFA and PDCD4 Expression in Gastrointestinal Cancer Patients: A Pilot Study. PLoS ONE 12, e0187310. doi:10.1371/journal.pone.0187310

Fritz, J., Strehblow, A., Taschner, A., Schoppf, S., Pasierbek, P., and Jantsch, M. F. (2009). RNA-regulated Interaction of Transportin-1 and Exportin-5 with the Double-Stranded RNA-Binding Domain Regulates Nucleocytoplasmic Shuttling of ADAR1. Mol. Cell. Biol. 29, 1487–1497. doi:10.1128/MCB.01519-08

FUNDING

This work was supported by National Key R&D Program of China (SQ2020YFF0426513), the Scientific Foundation of Fuzhou Municipal Health commission (2021-S-wp1), the Backbone Talents Training Project of Fujian provincial Health Commission (2020GGA072).
Pinto, Y., Buchumenski, I., Levanon, E. Y., and Eisenberg, E. (2018). Human RNA Editing Enzyme ADAR1 in Human Disease. WIREs RNA 7, e1330. doi:10.1002/wnan.1330

Shoshan, E., Mobley, A. K., Braeuer, R. R., Kamiya, T., Huang, L., Vasquez, M. E., et al. (2021). Reduced Adenosine-To-Inosine mRNA Editing Promotes Melanoma Growth and Metastasis. Nat. Cell Biol. 17, 311–321. doi:10.1038/s4138/ncb110

Silvestris, D. A., Scopa, C., Hanchi, S., Locatelli, F., and Gallo, A. (2020). De Novo A-to-I RNA Editing Discovery in InCreNA. Cancers 12, 2959. doi:10.3390/cancers12102959

Song, B., Shiromoto, Y., Minakuchi, M., and Nishikura, K. (2016). Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases. Genes 7, 129. doi:10.3390/genes7120129

Steffl, R., Oberstrass, F. C., Hood, J. L., Jourdan, M., Zimmermann, M., Skrivoska, L., et al. (2010). The Solution Structure of the ADAR2 dsRBM-RNA Complex Reveals a Sequence-Specific Readout of the Minor Groove. Cell 143, 225–237. doi:10.1016/j.cell.2010.09.026

Stellos, K., Gatsiou, A., Stamatelopoulos, K., Perisic Matic, L., John, D., Lunella, F., et al. (2016). Adenosine-to-inosine RNA Editing Controls Cathepsin S Expression in Atherosclerosis by Enabling HuR-Mediated Post-transcriptional Regulation. Nat. Med. 22, 1140–1150. doi:10.1038/nm.4172

Strehlow, A., Hallegger, M., and Jantsch, M. F. (2002). Nucleaseptosomal Distribution of Human RNA-Editing Enzyme ADAR1 Is Modulated by Double-Stranded RNA-Binding Domains, a Leucine-Rich Export Signal, and a Putative Dimerization Domain. Mol. Biol. Cell 13, 3822–3835. doi:10.1091/mbc.e01-03-0161

Su, R., Ma, J., Zheng, J., Liu, X., Liu, Y., Ruan, X., et al. (2020). PABPC1-induced Stabilization of BDFN-AS Inhibits Malignant Progression of Glioblastoma Cells through STAUI-Mediated Decay. Cell Death Dis. 11, 81. doi:10.1038/s41419-020-2187-9

Sun, T., Yu, W., Acevedo, A., Luo, J.-D., Wang, J., et al. (2021). Decoupling Expression and Editing Preferences of ADAR1 P150 and P110 Isoforms. Proc. Natl. Acad. Sci. U.S.A. 118, 2021757118. doi:10.1073/pnas.2021757118

Sun, Y., Fan, J., Wang, B., Meng, Z., Ren, D., Zhao, J., et al. (2020). The Aberrant Expression of ADAR1 Promotes Resistance to BET Inhibitors in Pancreatic Cancer by Stabilizing C-Myc. Am. J. Cancer Res. 10, 148–163

Takeda, S., Shigeyasu, K., Okugawa, Y., Yoshida, K., Mori, Y., Yano, S., et al. (2019). Activation of AZIN1 RNA Editing Is a Novel Mechanism that Promotes Invasive Potential of Cancer-Associated Fibroblasts in Colorectal Cancer. Cancer Lett. 444, 127–135. doi:10.1016/j.canlet.2018.12.009

Teoh, P. J., An, O., Chung, T.-H., Chooi, J. Y., Toh, S. H. M., Fan, S., et al. (2018). Aberrant Hypermethylation of the Myeloma Transcriptome by ADAR1 Confers Oncogenicity and Is a Marker of Poor Prognosis. Blood 132, 1304–1317. doi:10.1182/blood.2018-02-832576

Thomas, J. M., and Bea, P. A. (2017). How Do ADARs Bind RNA? New Protein-RNA Structures Illuminate Substrate Recognition by the RNA Editing ADARs. BioEssays 39, 1600187. doi:10.1002/bies.201600187

Torsin, L. I., Petrescu, G. E. D., Sabo, A. A., Chen, B., Brehar, F. M., Dragomir, M. P., et al. (2021). Editing and Chemical Modifications on Non-coding RNAs in Cancer: A New Tale with Clinical Significance. Int. J. Mol. Sci. 22, 581. doi:10.3390/ijms22020581
Velazquez-Torres, G., Shoshan, E., Ivan, C., Huang, L., Fuentes-Mattei, E., Paret, H., et al. (2018). A-to-I miR-378a-3p Editing Can Prevent Melanoma Progression via Regulation of PARVA Expression. Nat. Commun. 9, 461. doi:10.1038/s41467-018-02851-7

Walkley, C. R., and Li, J. B. (2017). Rewriting the Transcriptome: Adenosine-To-Inosine RNA Editing by ADARs. Genome Biol. 18, 205. doi:10.1186/s13059-017-1347-3

Wang, F., Wu, P., Gong, S., Chen, Y., Gao, J., Wang, S., et al. (2020). Aberrant TRPM4 Expression in MLL-Rearranged Acute Myeloid Leukemia and its Blockade Induces Cell Cycle Arrest via AKT/GLI1/Cyclin D1 Pathway. Cell Signal. 72, 109643. doi:10.1016/j.cellsig.2020.109643

Wang, L. X., X. I., So, E., Devlin, J. L., Zhao, Y., Wu, M., and Cheung, V. G. (2013). ADAR Regulates RNA Editing, Transcript Stability, and Gene Expression. Cell Rep. 5, 849–860. doi:10.1016/j.celrep.2013.10.002

Wang, Q., Hui, H., Guo, Z., Zhang, W., Hu, Y., He, T., et al. (2013). ADAR1 Regulates ARHGAP26 Gene Expression through RNA Editing by Disrupting miR-30b-3p and miR-573 Binding. RNA 19, 1525–1536. doi:10.1261/rna.041533.113

Wang, Q., Miyakoda, M., Yang, W., Khillan, J., Stachura, D. L., Weiss, M. J., et al. (2013). Stress-induced Apoptosis Associated with Null Mutation of ADAR1 RNA Editing Deaminase Gene. J. Biol. Chem. 279, 4952–4961. doi:10.1074/jbc.M310162200

Wang, R., Zhang, S., Chen, X., Li, N., Li, J., Jia, R., et al. (2018). CircNT5E Acts as a Sponge of miR-422a to Promote Glioblastoma Tumorigenesis. Cancer Res. 78, 4812–4825. doi:10.1158/0008-5472.CAN-18-0532

Xu, L.-D., and Öhman, M. (2018). ADAR1 Editing and its Role in Cancer. Genes 10, 12. doi:10.3390/genes10010012

Xu, T.-p., Liu, X.-x., Xia, R., Yin, L., Kong, R., Chen, W.-m., et al. (2015). SP1-induced Upregulation of the Long Noncoding RNA TINCR Regulates Cell Proliferation and Apoptosis by Affecting KLF2 mRNA Stability in Gastric Cancer. Oncogene 34, 5648–5661. doi:10.1038/onc.2015.18

Xu, T., Lei, T., Li, S.-Q., Mai, E.-H., Ding, F.-H., and Niu, B. (2020). DNAH17-AS1 Promotes Pancreatic Carcinoma by Increasing PPME1 Expression via Inhibition of miR-432-5p. World J. Gastroenterol. 26, 1745–1757. doi:10.3748/wjg.v26.i15.1745

You, X., Vlatkovic, I., Babic, A., Will, T., Epstein, I., Tushev, G., et al. (2015). Neural Circular RNAs Are Derived from Synaptic Genes and Regulated by Development and Plasticity. Nat. Neurosci. 18, 603–610. doi:10.1038/nn.3975

Yu, J., Zhang, C., Yu, Q., Yu, H., and Zhang, B. (2019). ADAR1 P110 Enhances Adhesion of Tumor Cells to Extracellular Matrix in Hepatocellular Carcinoma via Up-Regulating ITGA2 Expression. Med. Sci. Monit. 25, 1469–1479. doi:10.12699/msm.911944

Yujie Ding, M. M., Shi, X., Ji, J., and Su, Y. (2020). ADAR1p150 Regulates the Biosynthesis and Function of miRNA-149* in Human Melanoma. Biochem. Biophysical Res. Commun. 523, 900–907. doi:10.1016/j.bbrc.2019.12.110

Zhang, M., Fritsche, J., Roszik, J., Williams, L. J., Peng, X., Chiu, Y., et al. (2018). RNA Editing Derived Epitopes Function as Cancer Antigens to Elicit Immune Responses. Nat. Commun. 9, 3919. doi:10.1038/s41467-018-06405-9

Zhang, Z., and Carmichael, G. G. (2001). The Fate of dsRNA in the Nucleus. Cell 106, 463–476. doi:10.1016/s0092-8674(01)00466-4

Zhong, H., Wangxia, L., Fang, Y., Liu, Y., Zhao, Y., and Shi, Z. (2019). Circular RNA ARHGAP26 Is Over-expressed and its Downregulation Inhibits Cell Proliferation and Promotes Cell Apoptosis in Gastric Cancer Cells. Saudi J. Gastroenterol. 25, 119. doi:10.4103/sig.SIG_283_18

Zhu, J., Ye, J., Zhang, L., Xia, L., Hu, H., Jiang, H., et al. (2017). Differential Expression of Circular RNAs in Glioblastoma Multiforme and its Correlation with Prognosis. Transl. Oncol. 10, 271–279. doi:10.1016/j.tranon.2016.12.006

Zipeto, M. A., Court, A. C., Sadarangani, A., Delos Santos, N. P., Baliaan, L., Chun, H.-J., et al. (2016). ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell 19, 177–191. doi:10.1016/j.stem.2016.05.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Wang, Zhang, Liu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.